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Objective: Endometrial cancer with hematogenous metastases can be treated with chemotherapy. We
present a case of spontaneous pneumothorax that occurred when a solitary pulmonary endometrial
metastatic lesion was treated with paclitaxel plus carboplatin.
Case report: A 38-year-old female had stage II endometrial endometrioid adenocarcinoma. Solitary
bilateral pulmonary metastases developed after primary treatment. Complete remission accompanied by
a right spontaneous pneumothorax occurred during chemotherapy with paclitaxel plus carboplatin.
Conclusion: Rapid shrinkage of a pulmonary space-occupying tumor sometimes causes rare but life-
threatening spontaneous pneumothoraces. We report the ﬁrst case of a spontaneous pneumothorax
after using paclitaxel plus carboplatin in the treatment of endometrial cancer.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Chemotherapy plays a major role in treating endometrial cancer
patients who develop hematogenous spread or disseminated me-
tastases. Spontaneous pneumothoraces have been reported as one
of the therapeutic comorbidities of rapid regression of pulmonary
metastatic, space-occupying lesions after chemotherapy [1]. This
condition is relatively common in osteogenic tumors or sarcomas,
but is never reported in metastatic endometrial endometrioid
adenocarcinoma in the world. A spontaneous pneumothorax
developed in a patient with endometrial cancer after chemo-
therapy with paclitaxel and carboplatin (Bristol Myers Squibb, New
York, USA) following the rapid regression of pulmonary metastatic
lesions.
Case presentation
A 38-year-old woman (para 2) was diagnosed with poorly
differentiated endometrial endometrioid adenocarcinoma after
staging surgery. The International Federation of Gynecology and
Obstetrics (FIGO) stage was II (myometrial invasion was near-ncology, Department of Ob-
umber 92, Section 2, Chung-
hen).
bstetrics & Gynecology. Publishedwhole thickness, combined with endocervical stromal invasion).
Whole pelvic radiation therapy (total dose 5040 cGy) and intra-
vaginal brachytherapy were completed within 2 months after
surgery.
Unfortunately, solitary pulmonary metastases with bilateral
multiple nodules developed 3 months after the patient completed
radiation therapy. She declined a tissue biopsy. The primary sur-
gical ﬁeld was negative for recurrence. Salvage chemotherapy with
cisplatin (50mg/m2) plus doxorubicin (60 mg/m2; PA regimen) was
arranged, and complete remissionwas achieved after the ﬁrst three
courses of the PA regimen. She received three additional courses of
the PA regimen without any complications.
However, the pulmonary lesions relapsed rapidly 3 months
after completing the previous chemotherapy. The metastatic sites
expanded to not only the bilateral lung ﬁelds (Fig. 1), but also the
mediastinum. The primary surgical ﬁeld was negative for recur-
rence. The regimen was then changed to paclitaxel (175 mg/m2)
plus carboplatin (AUC5; TC regimen). Signiﬁcant radiographic
improvement was observed after three courses of the TC regimen
without any morbidity. She developed dyspnea, right chest
tightness, and a dry cough after the fourth course of the TC
regimen.
A right spontaneous pneumothorax was conﬁrmed. In addition,
all pulmonary metastatic nodules had almost disappeared in the
imaging study (Fig. 2). An emergent chest tube was inserted for
drainage and she recovered thereafter. An additional two courses ofby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Before chemotherapy with paclitaxel and carboplatin, imaging of bilateral lung
ﬁelds demonstrated multiple, variable-sized metastatic nodules.
Fig. 2. The image depicts a right spontaneous pneumothorax with almost total
regression of pulmonary nodules after four courses of chemotherapy with paclitaxel
and carboplatin. White arrows indicate right lung marking.
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piratory complications. Complete disease remission was again
noted by imaging and tumor marker studies after six courses of the
TC regimen were completed.
The third relapse was encountered 3 months after completing
the sixth course of the TC regimen. Right scalene lymphadenopa-
thy, which inﬁltrated the right jugular vein and the right brachial
plexus, caused right facial swelling, right hand disability, and
intractable neuralgia. Salvage chemotherapy of weekly paclitaxel
(80 mg/m2) and palliative local radiation therapy had little effect.
She died 28 months after the ﬁrst course of the PA regimen.
Discussion
A spontaneous pneumothorax is classiﬁed as primary and sec-
ondary based on its etiology. The mechanism underlying primary
spontaneous pneumothoraces is not fully understood. By contrast,
secondary spontaneous pneumothoraces occur from a variety of
diseases affecting the airways and parenchyma [2].
Malignancy, either primary lung malignancies or pulmonary
metastatic tumors, is one of the causes of secondary spontaneous
pneumothoraces. The most commonly reported cancer that causes
secondary pneumothorax is metastatic lung sarcoma [3,4]; in
addition, primary lung cancer [5], thyroid cancer [6], germ cell or
sex cord tumor [7e9], breast cancer [10], renal cell carcinoma [11],
and mediastinal lymphoma [12] have all been reported to cause
secondary spontaneous pneumothoraces. This might be the ﬁrst
report of a secondary spontaneous pneumothorax caused by
treating metastatic uterine endometrioid adenocarcinoma.
Several possible hypotheses of cancer treatment-related sec-
ondary pneumothoraces have been proposed. First, tumors
destruct the broncho-alveolar tissue, capillaries, or pleura directly
[2]. A second hypothesis involves the rapid shrinkage of space-
occupying tumors caused by various treatment modalities, such
as chemotherapy [5] or molecular targeted therapy [13]. Third,
molecular-targeted therapeutic agents, especially geﬁtinib, block
alveolar capillary growth and cause normal tissue damage [13]. In
the case presented herein, a chemosensitive pulmonary metastatic
malignancy may have rapidly shrunk after effective chemotherapy
and caused a spontaneous pneumothorax.
Endometrial cancer is the third most common gynecologic
malignancy in Taiwan. Advanced-stage endometrial cancer often
develops hematogenous or distant metastases rapidly and easily
after primary surgery and radiation therapy. Lung, liver, and bone
are the most frequent metastatic sites. Only systemic chemo-
therapy plays a role when distant metastases occur, but the optimal
regimen is still controversial. A combination of cisplatin and
doxorubicin, or paclitaxel and carboplatin are effective in disease
salvage and tolerable toxicity [14e16]. A triple combination of
cisplatin, paclitaxel, and doxorubicin gives rise to a better response
[15]. Not surprisingly, the toxicity is difﬁcult to tolerate in previous
heavily-treated cases.
In our case, we observed an excellent response to both our
chemotherapeutic regimens (PA and TC regimens) in treating he-
matogenous metastatic endometrioid adenocarcinoma. The
disease-free interval in our case was not as good as in serial cases
studies [16]. An extremely rare complication of a spontaneous
pneumothorax was encountered after dramatic tumor shrinkage
during chemotherapy. We hypothesize that the disappearance of
the pulmonary space-occupying metastatic lesion caused this rare
comorbidity. Delayed diagnosis of a pneumothorax is serious and
life-threatening. This might be the ﬁrst case report of a sponta-
neous pneumothorax developing after the combination of pacli-
taxel and carboplatin for the treatment of metastatic endometrial
cancer.
J.-R. Chen, Y.-C. Yang / Taiwanese Journal of Obstetrics & Gynecology 53 (2014) 245e247 247In conclusion, we should be vigilant for any respiratory symp-
toms after chemotherapy with rapid pulmonary tumor shrinkage.
Spontaneous pneumothorax is a rare but still possible condition
that is sometimes life-threatening.
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